2013-11-13T10:33:34-06:00 2012-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1700 BELLEVUE WA 98004 990 2012-01-01 911608978 INFECTIOUS DISEASE RESEARCH INSTITUTE INFE 2063810883 1616 EASTLAKE AVE E NO 400 SEATTLE WA 98102 H STEWART PARKER 2063810883 2013-11-12 1 JANE M SEARING P00000565 4254544919 2013-11-12 2012 2016-02-25 16:41:14Z H STEWART PARKER 1616 EASTLAKE AVE E NO 400 SEATTLE WA 98102 23811958 0 X WWW.IDRI.ORG X 1993 WA DEVELOP VACCINES, DIAGNOSTICS & DRUGS TO PREVENT, DETECT & TREAT INFECTIOUS DISEASES OF POVERTY. 10 8 149 8 503963 -134476 14410786 20127852 2463111 2779545 53600 38260 288928 10813 17216425 22956470 0 16150 0 0 9319146 10989760 0 0 304136 13965812 13379680 23284958 24385590 -6068533 -1429120 42428324 49538156 3595070 12130421 38833254 37407735 X DEVELOP VACCINES, DIAGNOSTICS AND NOVEL DRUGS TO PREVENT, DETECT AND TREAT INFECTIOUS DISEASES OF POVERTY. 0 0 9553176 16150 886066 VACCINE RESEARCH - VACCINES ARE COMPOSED OF SEVERAL COMPONENTS: (A) ANTIGENS THAT STIMULATE THE IMMUNE SYSTEM TO COMBAT A PARTICULAR INFECTIOUS DISEASE AND (B) ADJUVANTS, SUBSTANCES THAT ENHANCE THE ABILITY OF ANTIGENS TO STIMULATE THE BODY'S IMMUNE RESPONSE. PUT ANOTHER WAY, ANTIGENS DETERMINE THE SPECIFICITY OF THE IMMUNE RESPONSE (E.G., FOR INFLUENZA OR TETANUS) WHEREAS ADJUVANTS AFFECT THE MAGNITUDE OF THE BODY'S IMMUNE RESPONSE.IDRI'S SCIENTISTS ARE USING THE LATEST TECHNIQUES TO IDENTIFY THE BEST ANTIGENS FOR NEW VACCINES TO COMBAT DISEASES THAT IMPACT GLOBAL HEALTH. IDRI'S CANDIDATE VACCINE FOR LEISHMANIASIS IS CURRENTLY IN CLINICAL TESTING AND VACCINES FOR TUBERCULOSIS AND LEPROSY ARE POISED TO START CLINICAL TESTING. 5829705 23187 ADJUVANT RESEARCH - AN IMPORTANT AREA OF RESEARCH FOR IDRI IS IMPROVING ADJUVANTS AND HOW THEY ARE COMBINED WITH ANTIGENS TO IMPROVE VACCINES. BETTER ADJUVANTS CAN INCREASE AND BROADEN THE IMMUNE RESPONSE TO AN ANTIGEN, AS WELL AS REDUCE THE AMOUNT OF ANTIGEN NECESSARY FOR A GOOD RESPONSE. THIS LAST CHARACTERISTIC CAN MAKE OUR VACCINE STOCKS GO FURTHER AND POTENTIALLY REDUCE THE COST. IDRI IS COLLABORATING WITH PARTNERS ALL OVER THE WORLD TO IMPROVE VACCINES FOR ADDITIONAL CHALLENGING DISEASES SUCH AS MALARIA AND PANDEMIC INFLUENZA. 2389366 27837 TUBERCULOSIS DRUG DISCOVERY - IN ADDITION TO WORKING ON BETTER DIAGNOSTIC TESTS AND VACCINES FOR TUBERCULOSIS (TB), IDRI HAS AN EARLY DISCOVERY PROGRAM TO IDENTIFY NEW CHEMICAL COMPOUNDS THAT ARE CANDIDATES TO TREAT TB. THERE IS AN URGENT NEED FOR NEW TYPES OF TB DRUGS; THE ONES CURRENTLY USED WERE DEVELOPED OVER 40 YEARS AGO AND WE ARE FACED WITH AN INCREASING THREAT FROM BACTERIA THAT ARE RESISTANT TO MANY OF THESE DRUGS. THE DRUG DISCOVERY GROUP COMBINES THE SKILLS OF MICROBIOLOGISTS, CHEMISTS, AND MOLECULAR BIOLOGISTS AND COLLABORATES WITH PHARMACEUTICAL COMPANIES AND OTHER RESEARCH INSTITUTIONS TO MAXIMIZE OUR CHANCE OF SUCCESS. 127542 1802168 MANUFACTURING - ONCE A VACCINE CANDIDATE HAS BEEN IDENTIFIED IN THE RESEARCH LAB, THE NEXT CHALLENGE IS TO APPLY THAT DISCOVERY TO THE CLINICAL SETTING. A NECESSARY PART OF THIS TRANSITION IS TO PRODUCE VACCINES UNDER CONTROLLED CONDITIONS SO THAT THEY ARE SUITABLE FOR USE IN HUMAN STUDIES. IDRI HAS DEVELOPED THE TYPE OF MANUFACTURING CAPABILITY REQUIRED TO MOVE A VACCINE FROM LATE STAGE RESEARCH TO EARLY CLINICAL STUDIES. 1770225 40287 OTHER ACTIVITIES - IDRI'S CLINICAL GROUP DESIGNS AND CONDUCTS EARLY STAGE CLINICAL TRIALS TO TEST THE VACCINE CANDIDATES IDENTIFIED BY IDRI SCIENTISTS OR COLLABORATORS. THROUGH OUR NETWORK OF GLOBAL CONNECTIONS, THE CLINICAL TEAM IS ABLE TO LAUNCH CLINICAL TRIALS ALMOST ANYWHERE IN THE WORLD. 1897767 1842455 19670014 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 37 0 1 149 1 1 1 0 0 0 0 0 0 0 0 0 X 10 8 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 0 X THERESE COAD AND PATRICIA MIELE 2063810883 1616 EASTLAKE AVE E SUITE 400 SEATTLE WA 98102 ERIC EASOM 5.00 X X 0 0 0 DAVID WEBSTER 5.00 X X 0 0 0 DAVID MAKI JD 5.00 X X 0 0 0 CYNTHIA HEALY PHD 5.00 X 0 0 0 CHRIS HENTSCHEL PHD 5.00 X 0 0 0 H STEWART PARKER 50.00 X X 374214 0 11096 DAVID PERRY 5.00 X 0 0 0 FRANKLYN PRENDERGAST MD 5.00 X 0 0 0 STEVEN REED PHD 50.00 X X 355340 0 22941 MASSIMO RADAELLI 5.00 X 0 0 0 ERIK IVERSON JD LLM 40.00 X 222137 0 17539 CURT MALLOY 40.00 X 207100 0 21489 ROBERT LIN 40.00 X 36624 0 4079 ANNA MARIE BECKMANN 40.00 X 152344 0 20454 RHEA COLER 40.00 X 153241 0 3162 JOSHUA ODINGO 40.00 X 129275 0 19805 FRANCO PIAZZA 40.00 X 242278 0 5545 WINSTON WICOMB 40.00 X 137040 0 20214 KAREN KINCH 40.00 X 125506 0 14017 2135099 0 160341 20 1 1 0 GENNOVA BIOPHARMACEUTICALS LIMITED T 184 MIDC BHOSARI PUNE IN 411 026 RESEARCH 502425 CEBU LEPROSY & TUBERCULOSIS RSCH FOUNDAT PO BOX 277 CEBU CITY RP 6000 RESEARCH 466345 COVANCE CLINICAL RESEARCH UNIT 3402 KINSMAN BLVD MADISON WI 53704 RESEARCH 425898 CHARLES RIVER LABORATORIES 542 1ST AVE S SEATTLE WA 98104 RESEARCH 411520 SEED IP LAW GROUP LLC 701 FIFTH AVENUE SUITE 5400 SEATTLE WA 981047092 LEGAL SERVICES 337613 14 1368 7517219 12609265 370484 20127852 CONTRACT REVENUE 541700 1802168 1802168 VIVARIUM INCOME 541700 496163 496163 OPTION FEE REVENUE 541700 456660 456660 RESEARCH REVENUE 541700 24554 24554 2779545 38260 38260 657929 657929 200572 7800 855488 0 -654916 7800 -647116 7800 -654916 22956470 2283382 503963 41273 16150 16150 1268447 469390 725436 73621 7767351 6201296 1429889 136166 109368 90826 17715 827 1164586 867679 287710 9197 680008 537206 134455 8347 403546 316803 86743 113207 113207 93210 14298 39283 39629 58521 7035 51486 165381 34221 131160 171875 30292 141583 323464 323464 2335134 2147665 165146 22323 443651 321036 120189 2426 56861 12259 44602 945033 746576 186857 11600 79403 19116 60287 LAB SUPPLIES 3672890 3560848 112042 SUBCONTRACTS 2795227 2720281 74946 CONTRACTED SERVICES 1224636 1224636 REPAIRS & MAINTENANCE 290616 221864 68752 207025 110537 96488 24385590 19670014 4411440 304136 1814379 4637406 21406644 15811089 16776863 18171269 373927 1231667 101879 207037 14324893 4846183 1951709 9478710 250 250 2673 728 42428324 49538156 2312315 2445651 1104589 395055 178166 9289715 3595070 12130421 X 2908320 3085312 35924934 34322423 38833254 37407735 42428324 49538156 -1429120 3601 0 X 0 1 X 1 1 1 X UNIVERSIDAD CENTRAL DE VENEZUELA CARACAS VE UNIVERSITY OF KHARTOUM KHARTOUM SU CASE WESTERN RESERVE UNIVERSITY CLEVELAND OH BANARAS HINDU UNIVERSITY VARANASI IN UNIVERSIDAD PERUANA CAGETANO HEREDIA LIMA PE RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 8189174 484102 7705072 6135719 4362081 1773638 9478710 DEFERRED RENT 9289715 9289715 23291523 3601 -323464 -319863 23611386 -654916 -654916 22956470 24717042 654916 654916 24062126 323464 323464 24385590 PART XI, LINE 2D - OTHER ADJUSTMENTS: ROYALTY EXPENSES INCLUDED IN INCOME ON FINANCIAL STATEMENTS -323,464. PART XI, LINE 4B - OTHER ADJUSTMENTS: NET RENTAL INCOME INCLUDED IN REVENUE ON TAX RETURN -654,916. PART XII, LINE 2D - OTHER ADJUSTMENTS: NET RENTAL INCOME INCLUDED IN REVENUE ON TAX RETURN 654,916. PART XII, LINE 4B - OTHER ADJUSTMENTS: ROYALTY EXPENSES INCLUDED IN INCOME ON FINANCIAL STATEMENTS 323,464. EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES RESEARCH 469793 EAST ASIA AND THE PACIFIC - 0 0 PROGRAM SERVICES RESEARCH 474695 SOUTH AMERICA 0 0 PROGRAM SERVICES RESEARCH 164491 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES RESEARCH 929 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES RESEARCH 92350 SOUTH ASIA 0 0 PROGRAM SERVICES RESEARCH 679940 NORTH AMERICA 0 0 PROGRAM SERVICES RESEARCH 5682 0 0 0 0 0 0 1887880 0 1887880 0 0 0 0 0 0 1 WHITMAN COLLEGE 345 BOYER AVE WALLA WALLA WA 99362 910567740 UNIVERSITY 9000 GENERAL SUPPORT 1 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: ALL PAYMENTS MADE FOR PROGRAM SERVICES WITHIN THE U.S. ARE BASED ON LEGAL AGREEMENTS BETWEEN IDRI AND THE PARTY RECEIVING PAYMENT. THESE AGREEMENTS INCLUDE REQUIREMENTS FOR BOTH PROGRESS AND FINANCIAL REPORTING BASED ON TIME PERIODS OR MILESTONE ACHIEVEMENTS. REPORTS ARE REVIEWED BY SCIENTIFIC AND ADMINISTRATIVE STAFF TO ENSURE THAT THE GOALS OF THE AGREEMENT AND ANY SPECIFIC FINANCIAL RESTRICTIONS ARE BEING MET BEFORE FURTHER PAYMENT IS MADE. MOST AGREEMENTS ALSO CONTAIN A CLAUSE GIVING IDRI THE RIGHT TO AUDIT FINANCIAL RECORDS OF THE PARTY IF NEEDED. X X X X 0 0 0 0 0 0 0 0 0 H STEWART PARKER 374214 0 0 0 0 0 5500 0 5596 0 385310 0 0 0 STEVEN REED PHD 355340 0 0 0 0 0 5500 0 17441 0 378281 0 0 0 ERIK IVERSON JD LLM 222137 0 0 0 0 0 175 0 17364 0 239676 0 0 0 CURT MALLOY 207100 0 0 0 0 0 4125 0 17364 0 228589 0 0 0 ANNA MARIE BECKMANN 152344 0 0 0 0 0 3106 0 17348 0 172798 0 0 0 RHEA COLER 153241 0 0 0 0 0 3000 0 162 0 156403 0 0 0 FRANCO PIAZZA 242278 0 0 0 0 0 4845 0 700 0 247823 0 0 0 WINSTON WICOMB 137040 0 0 0 0 0 2850 0 17364 0 157254 0 0 0 KAREN KINCH 125506 0 0 0 0 0 2563 0 11454 0 139523 0 0 0 X LAB SUPPLIES 2 33684 FMV X LAB EQUIPMENT 1 321800 FMV 0 0 0 0 METHOD FOR DETERMINING NUMBER OF CONTRIBUTORS: PART I, COLUMN (B): THE AMOUNT IN COLUMN B IS BASED ON THE NUMBER OF CONTRIBUTORS DURING THE YEAR. FORM 990, PART 1, LINE 6: THERE WERE EIGHT VOLUNTEER BOARD MEMBERS DURING THE YEAR. BOARD MEMBERS PARTICIPATE IN STRATEGIC PLANNING, EXECUTIVE LEADERSHIP RECRUITMENT AND SELECTION, INTELLECTUAL PROPERTY STRATEGY, AND IDENTIFICATION OF INSTITUTIONAL LIABILITY. THEY COME FROM A VARIETY OF BACKGROUNDS AND DEMONSTRATE FINANCIAL EXPERTISE, REAL ESTATE LEASING/PURCHASING EXPERTISE, BIO-MEDICAL NOT-FOR-PROFIT EXPERTISE, AND AN UNDERSTANDING OF BUSINESS AND BIOTECH LICENSING. FORM 990, PART VI, SECTION A, LINE 8B BOARD MEETINGS MINUTES ARE DOCUMENTED AND APPROVED AT THEN NEXT MEETING BY THE BOARD. COMMITTEE MEETINGS ARE NOT DOCUMENTED BY REQUEST OF THE COMMITTEE MEMBERS. FORM 990, PART VI, SECTION B, LINE 11 A DRAFT COPY OF THE FORM 990 AND FORM 990-T IS PRESENTED TO THE AUDIT COMMITTEE FOR REVIEW. THE AUDIT COMMITTEE REVIEWS AND APPROVES THE FORM 990 AND 990-T ON BEHALF OF THE IDRI BOARD OF DIRECTORS. ALL BOARD MEMBERS RECEIVE A COPY OF THE FORM 990 AND 990-T PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C EACH JANUARY, MEMBERS OF THE BOARD OF DIRECTORS AND SENIOR MANAGEMENT ARE GIVEN A COPY OF THE CONFLICT OF INTEREST POLICY. THEY ARE REQUIRED TO FILL IT OUT AND RETURN IT BY THE FIRST BOARD MEETING - USUALLY SOMETIME IN THE FIRST QUARTER. THE SENIOR VICE PRESIDENT OF OPERATIONS AND GENERAL COUNSEL REVIEWS THE QUESTIONNAIRES AND SUMMARIZES THE RESULTS. THE RESULTS ARE COMMUNICATED TO THE BOARD OF DIRECTORS. TO THE EXTENT THAT THERE ARE ANY CONFLICTS, THE MEMBER IS RECUSED FROM ANY DECISION MAKING THAT WOULD INCLUDE THE CONFLICT. WHEN THE OCCASION ARISES, THOSE MEMBERS ALSO REMIND THE GROUP (MANAGEMENT TEAM OR BOARD) THAT THERE IS A POTENTIAL CONFLICT WHEN SPECIFIC DISCUSSION TOPICS ARISE. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE CONDUCTED A FULL CEO PERFORMANCE AND COMPENSATION REVIEW, INITIATED IN JANUARY 2013 WITH A REPORT AT THE APRIL 2013 BOARD MEETING, USING AN OUTSIDE INDEPENDENT CONSULTANT. THE REPORT IS IN THE BOARD MATERIALS AND IN THE PERSONNEL FILE. THE DECISIONS ARE IN THE COMPENSATION COMMITTEE NOTES. COMPARATIVE COMPENSATION INFORMATION WAS USED FROM THE CULPEPPER AND RADFORD PROFESSIONAL COMPENSATION FIRMS. THE BOARD CHAIR ALSO DOES AN ANNUAL REVIEW OF ALL OTHER OFFICERS AND KEY EMPLOYEES AND WORKS WITH THE HUMAN RESOURCES DEPARTMENT TO DETERMINE IF THE COMPENSATION IS ADEQUATE. IF AN ADJUSTMENT IS DEEMED NECESSARY, THE BOARD CHAIR CONVENES THE COMPENSATION COMMITTEE AND THE ADJUSTMENT IS ADDRESSED. THE BOARD CHAIR REPORTS BACK TO THE HUMAN RESOURCES DEPARTMENT WHO FOLLOWS THROUGH WITH THE COMMITTEE'S RECOMMENDATION. FORM 990, PART VI, SECTION C, LINE 19 WHEN IDRI RECEIVES REQUESTS TO SHARE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS, THE PRESIDENT REVIEWS THE REQUEST AND, IF WARRANTED, DISCUSSES THE REQUEST WITH THE IDRI FINANCE COMMITTEE OR OTHER RELEVANT GOVERNING COMMITTEES. SUCH REQUESTS ARE TAKEN VERY SERIOUSLY IN LIGHT OF OUR BELIEF THAT NON-PROFIT ORGANIZATIONS SHOULD BE AS TRANSPARENT AS POSSIBLE.